FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
The reporting (7)
- BMS welcomes new multiple myeloma drug as generics batter current portfolio BioSpace · 3d ago
- OncLive Weekly News Quiz (8/14/2026): Did You Catch This Week's Myeloma, Lung Cancer, and Polycythemia Vera Updates? OncLive · 3d ago
- Bristol Myers Squibb (BMY) Wins FDA Approval, Is The Stock Fully Priced? Yahoo Finance · 3d ago
- U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse Bristol Myers Squibb · 3d ago
- US FDA approves Bristol Myers' blood cancer treatment reuters.com · 3d ago
- BMS bags first FDA approval for CELMoD franchise with Zenbexus multiple myeloma nod Fierce Pharma · 3d ago
- FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class STAT · 3d ago broke it first
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Related trends
Credit card issuer Synchrony partners with OpenAI for ChatGPT shopping
Credit card issuer Synchrony has partnered with OpenAI to bring store cards and shopping offers into ChatGPT.
The Surprising Reason This Biotech Plummeted 69%
EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.
China's recovery sputters as consumption, output lose steam
China's economic recovery is losing momentum as retail sales, output, and investment slow down.
Alibaba to Sell Videogame Business for at Least $1.5 Billion
Alibaba moves to sell its videogame business to prioritize artificial intelligence and e-commerce.
Big investors hunt for tomorrow's AI winners as capex angst fades
Major investors are shifting focus toward emerging artificial intelligence opportunities as capital expenditure concerns diminish.
Private credit under strain as troubled loans swell
Private credit faces high stress levels and troubled loans, while industry leaders debate systemic risks.